Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Intellia Therapeutics, Inc. - Common Stock
(NQ:
NTLA
)
11.32
+0.55 (+5.11%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Intellia Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
3 Gene Editing Stocks That Could Grow Your Wealth
↗
July 17, 2024
Investors looking for gene editing stocks of cutting edge technology firms should consider these biotech stocks.
Via
InvestorPlace
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
↗
July 17, 2024
Explore gene-editing stocks with potential to become multibaggers as the industry advances in treating genetic disorders.
Via
InvestorPlace
Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday
↗
July 12, 2024
Via
Benzinga
3 Profitable CRISPR Stocks Earning Analysts’ Praise
↗
July 09, 2024
Revolutionary gene-editing technologies provide promise for investors seeking the most profitable CRISPR stocks today and in the future.
Via
InvestorPlace
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
↗
July 09, 2024
Finding undervalued gene editing stocks is easy, but having the patience to stick with them is the challenge.
Via
InvestorPlace
Unveiling 6 Analyst Insights On Intellia Therapeutics
↗
June 24, 2024
Via
Benzinga
Cracking The Code: Understanding Analyst Reviews For Intellia Therapeutics
↗
June 04, 2024
Via
Benzinga
The Bull Case for Intellia Therapeutics Stock Just Got Even Stronger
↗
July 09, 2024
An improbable but serious risk facing the company's investors just got minimized.
Via
The Motley Fool
The 3 Best Gene Editing Stocks to Buy in July 2024
↗
July 08, 2024
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks.
Via
InvestorPlace
3 Pharma Stocks Already Ushering in the Next Biotech Boom
↗
July 08, 2024
So long as diseases afflict the human condition, there will likely always be a need for pharma stocks. Here are three to consider.
Via
InvestorPlace
The 3 Best Biotech Stocks to Buy in July 2024
↗
July 05, 2024
For investors looking for promising biotech investments should explore the best biotech stocks to watch in July 2024.
Via
InvestorPlace
Cathie Wood's Ark Invest Dumps Another $3.25M Worth Of Tesla Shares Amid Searing Q2 Deliveries Rally
↗
July 03, 2024
Via
Benzinga
Cathie Wood's Ark Invest Sells Tesla Shares Worth $14.5M Amid Rally Driven By Q2 Delivery Numbers, Picks Up Palantir Shares Again Today
↗
July 02, 2024
Via
Benzinga
3 Stocks Cathie Wood Just Bought to Get Back on Track in the Second Half of 2024
↗
July 02, 2024
The popular growth investor is making big moves in July to bounce back after a rough start this year.
Via
The Motley Fool
Treasure Hunt: 3 Biotech Stocks Wall Street Hasn’t Discovered Yet
↗
June 28, 2024
Undiscovered biotech stocks can be risky but rewarding, especially when it involves mid-cap stocks with promise and no profit.
Via
InvestorPlace
You’ve Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.
↗
June 27, 2024
The best gene editing stocks to buy are those with strong tehnogical applications and genuine commercialization prospects.
Via
InvestorPlace
Cathie Wood's Ark Invest Acquires $7.3M Worth Of Shares In This Promising Netflix Competitor, Sells Off Coinbase Stock Amid Bitcoin Slump
↗
June 26, 2024
On Wednesday, Cathie Wood-led Ark Invest made significant trades in Roku Inc (NASDAQ:ROKU) and Coinbase Global Inc (NASDAQ:COIN), amidst a volatile market.
Via
Benzinga
3 Gene Editing Stocks That Could Make Your Grandchildren Rich
↗
June 25, 2024
Explore gene-editing stocks with long-term growth potential, offering innovative solutions to previously untreatable conditions.
Via
InvestorPlace
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
June 24, 2024
Via
Benzinga
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
↗
June 24, 2024
Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach.
Via
Benzinga
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for June 2024
↗
June 21, 2024
Investors looking for companies with high growth potential should consider investing in these three strong buy Cathie Wood stocks.
Via
InvestorPlace
Avidity Biosciences And CleanSpark Were Among The 10 Biggest Mid-Cap Stock Gainers Last Week (June 9-June 15): Are These In Your Portfolio?
↗
June 16, 2024
Top mid-cap performers: Avidity Biosciences, Iris Energy, Hims & Hers Health, John Wiley & Sons, Element Solutions, CleanSpark, Enovix Corp, Axcelis Tech, Intellia Therapeutics, Korn Ferry.
Via
Benzinga
Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness
↗
June 10, 2024
On Monday, Cathie Wood-led Ark Invest made a significant move by reducing its holdings in Robinhood Markets Inc (NASDAQ:HOOD). This decision came amidst a period of market fluctuations and followed a...
Via
Benzinga
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought
↗
June 09, 2024
These companies could generate explosive growth over time.
Via
The Motley Fool
These 2 Words Are Why Intellia Therapeutics Could Be a Smart Buy Right Now
↗
June 08, 2024
Neither word has anything to do with money -- at least not yet.
Via
The Motley Fool
Cathie Wood-Led Ark Invest Buys $9.9M Worth Of Amazon Shares, Also Picks Up Reddit Stock
↗
June 06, 2024
Via
Benzinga
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
↗
June 06, 2024
The widely followed growth investor made big moves as May came to a close.
Via
The Motley Fool
The 3 Best Biotech Stocks to Buy in June 2024
↗
June 05, 2024
Explore the best biotech stocks to buy in June 2024, with insights on Protagonist, BridgeBio and Intellia.
Via
InvestorPlace
Cathie Wood Is Buying the Dip on These 2 Biotech Stocks. Should You?
↗
June 04, 2024
In keeping with Cathie Wood's style, these picks are riskier than average.
Via
The Motley Fool
Why Intellia Therapeutics Shares Are Trading Higher Monday
↗
June 03, 2024
Intellia's NTLA-2002 is an experimental CRISPR based gene-editing therapy being developed as a one-time treatment for hereditary angioedema (HAE). The company announced the single does treatment led to...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
